XSPY PHAR Stock Nasdaq Stockholm
Equities
SE0009973563
Biotechnology & Medical Research
Sales 2024 * | 131M 12.06M 0 | Sales 2025 * | 789M 72.62M 0 | Capitalization | 1.28B 118M 0 |
---|---|---|---|---|---|
Net income 2024 * | 596M 54.86M - | Net income 2025 * | - | EV / Sales 2024 * | 5.01 x |
Net cash position 2024 * | 620M 57.06M 0 | Net cash position 2025 * | - 0 - | EV / Sales 2025 * | 1.62 x |
P/E ratio 2024 * |
1.91
x | P/E ratio 2025 * |
-
| Employees | - |
Yield 2024 * |
2.45% | Yield 2025 * |
-
| Free-Float | 51.2% |
Managers | Title | Age | Since |
---|---|---|---|
Per Andersson
CEO | Chief Executive Officer | 57 | 06-08-31 |
Director of Finance/CFO | 52 | Feb. 07 | |
Thomas Walz
CTO | Chief Tech/Sci/R&D Officer | - | 22-08-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 71 | 14-12-31 | |
Carl-Johan Spak
BRD | Director/Board Member | 68 | 14-12-31 |
Chairman | 70 | 22-05-18 |
1st Jan change | Capi. | |
---|---|---|
-1.51% | 104B | |
+3.22% | 97.42B | |
+1.66% | 22.2B | |
-16.53% | 21.23B | |
-9.26% | 18.33B | |
-42.33% | 16.35B | |
-20.09% | 15.06B | |
+5.47% | 13.98B | |
+28.85% | 11.66B |